1.
SESSION III: Biomarkers in interstitial
lung diseases: is it possible to monitor
and better treat the patients?
BRN Seminar: BIOMARKERS IN RESPIRATORY
DISEASES
Dr. Jacob Sellarés, MD
• Interstitial Lung Disease Program Director, Servei de Pneumologia,
Institut Clínic Respiratori (ICR), Hospital Clinic, Barcelona
• Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
University of Barcelona.

2.
Am J Respir Crit Care Med Vol 198, Iss 5, pp e44–e68, Sep 1, 2018

3.
Biomarkers in interstitial lung diseases:
is it possible to monitor and better
treat the patients?
The answer is NO, IT IS NOT
POSSIBLE

4.
THE END OF BIOMARKERS IN
ILDs?
My last submitted grant:
The strategic objective of this project is the
translational nature and consists of
identifying new biomarkers
associated with the clinical and biological
heterogeneity of ILDs to stratify patients on
solid physiopathological bases and thus
advance towards the treatment of disease
accuracy.

5.
Biomarkers
a) Risk or predisposition
b) Diagnostic
c) Pronostic
d) Therapeutic

6.
Problems
• Difiiculties:
• To define their role in Guidelines
• Clinical application
• Expensive
• Slow
• Heterogeneity
• Only one biomarker?
• Better than other markers?:
• Functional: FVC
• Radiological

7.
Biomarkers in interstitial lung diseases:
is it possible to monitor and better
treat the patients?
The answer is NO, IT IS NOT
POSSIBLE with the current
ones, but in the future….

8.
sellares@clinic.cat
pneumompid@clinic.cat
Muchas Gracias
¡¡¡¡Muchas gracias!!!